# Blueprint Medicines Corporation

Blueprint Medicines Corporation is an other based in Cambridge, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** 45 Sidney Street, Cambridge, MA 02139, United States
- **Assets under management:** Undisclosed
- **Website:** www.blueprintmedicines.com
- **LinkedIn:** https://www.linkedin.com/company/blueprint-medicines

## Regulatory record

- **Reports private funds:** No

## About

Blueprint Medicines, a Sanofi company, is a global biopharmaceutical company that invents life-changing medicines.

## Sectors

- Biotech
- Pharmaceuticals
- Oncology
- Allergy/Inflammation

## Offices

- Baarerstrasse 8, 6300 Zug, Switzerland

## Questions

### Who leads investment decisions at Blueprint Medicines?

Blueprint Medicines is a Sanofi company, so strategic and capital allocation decisions are overseen by Sanofi's executive team. The company's own leadership includes a CEO and board appointed by Sanofi; however, public disclosures do not name a single investment decision-maker at the Blueprint level.

### How does Blueprint Medicines source its drug discovery?

Blueprint Medicines combines internal R&D with AI/ML tools for drug design, focusing on kinase inhibitors and targeted protein degradation. The company's pipeline originates from its own discovery platform, which includes structural biology, translational medicine, and computational chemistry capabilities.

### Is Blueprint Medicines a biotech or a pharmaceutical company?

Blueprint Medicines operates as a global biopharmaceutical company with both discovery-stage and commercial-stage assets. It has two approved medicines — AYVAKIT in the U.S. and Europe for systemic mastocytosis and GIST — and a pipeline of investigational therapies, placing it in the commercial biotech category.

### What therapeutic areas does Blueprint Medicines focus on?

The company targets allergic/inflammatory diseases and oncology/hematology. Specific areas include systemic mastocytosis, chronic urticaria, breast cancer, and other solid tumors. The pipeline includes programs for mast cell-mediated diseases and multiple cancer types.

## Related profiles

- [Galderma S.A.](https://altss.com/profile/galderma-sa)
- [Huitung Investments](https://altss.com/profile/huitung-investments)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/blueprint-medicines-corporation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology